Tryvio
(Aprocitentan)Phase 3Small molecule
Idorsia Pharmaceuticals Ltd.Aprocitentan is a blood pressure medication that works by relaxing blood vessels, making it easier for the heart to pump blood throughout the body. It helps prevent serious complications from high blood pressure, such as heart disease, stroke, and kidney damage.[1] Tryvio is currently being investigated across 3 indications[3], with its most advanced program in Phase 3.[1]
Tryvio is one of 84 small molecule programs targeting Essential Hypertension. It is currently in Phase 3.
3
Indications
11
Total Trials
0
Active Trials
83
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Tryvio
Idorsia Pharmaceuticals Ltd.Phase 3
Edarbi
TakedaPreclinical
Benicar
NovartisPreclinical
Apresoline
NovartisPreclinical
Zebeta
TevaPreclinical
Edarbi
TakedaPreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Avastin
BBio-Thera Solutions
Preclinical
Disalcid
JJoslin Diabetes Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Homeostasis1 trial
Statin1 trial
Midazolam1 trial
5 more indications
Essential Hypertension1 trial
Women1 trial
Hypertension1 trial
Chronic Kidney Disease1 trial
Regulatory
FDA Approval Timeline[4]
Mar 19, 2024
TRYVIO
NDA NDA217686
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aprocitentan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Tryvio. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company